Johnson & Johnson (NYSE: JNJ) today announced groundbreaking topline results from the Phase 3 MajesTEC-9 study, demonstrating that TECVAYLI® (teclistamab-cqyv) monotherapy significantly improves outcomes for patients with relapsed or refractory multiple myeloma.
The study found that TECVAYLI® reduced the risk of disease progression or death by a staggering 71% compared to the current standard of care. These results mark a potential shift in the treatment landscape, suggesting that this immunotherapy could become a new standard as early as a patient’s first relapse.
Transforming Outcomes in High-Need Populations
The MajesTEC-9 trial focused on a particularly challenging patient population: those who had received one to three prior lines of therapy and were predominantly refractory (non-responsive) to anti-CD38 antibodies and lenalidomide, two of the most common treatments for the disease.
Key findings from the first pre-specified interim analysis include:
- 71% reduction in the risk of disease progression or death (PFS).
- 40% reduction in the risk of death (OS) compared to standard-of-care regimens (pomalidomide, bortezomib, and dexamethasone [PVd] or carfilzomib and dexamethasone [Kd]).
- Superiority in Early Relapse: The data confirms benefits as early as the second line of therapy, offering hope to patients who often face dwindling options after initial treatments fail.
A New Frontier for Bispecific Antibodies
TECVAYLI® is a first-in-class bispecific T-cell engager (BiTE) antibody. It works by “bridging” the body’s own T-cells to the cancer cells, specifically targeting the B-cell maturation antigen (BCMA) on myeloma cells and the CD3 receptor on T-cells. This dual binding activates the immune system to directly attack and destroy the cancer.
Previously approved for patients who had undergone four or more lines of therapy, these new Phase 3 results support moving TECVAYLI® much earlier into the treatment sequence.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Safety and Next Steps
The safety profile observed in MajesTEC-9 was consistent with previous trials of TECVAYLI®, with no new safety concerns identified. Common side effects included Cytokine Release Syndrome (CRS) and neurologic toxicity, which were managed through established clinical protocols.
Due to the overwhelming efficacy of the drug, an Independent Data Monitoring Committee (IDMC) has recommended unblinding the study. Johnson & Johnson plans to present the full data set at an upcoming major medical meeting and will submit the findings to global health authorities to expand the drug’s approved use.
Last Modified:
